.Merck beats earnings desires, rears purchases expectation on solid need for best drugs like Keytruda CNBCMerck & Co. (MRK US) Beats Earnings Projections as Keytruda Sales Growth BloombergMerck Stock: Pharma Titan Posts Solid Outcomes, But Outlook Drops Short Entrepreneur's Organization DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck trumps revenue and sales desires in the middle of Keytruda strong point, but delivers combined full-year outlook MarketWatch.